First Trust Direct Indexing L.P. Has $1.12 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

First Trust Direct Indexing L.P. raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,066 shares of the company’s stock after purchasing an additional 377 shares during the period. First Trust Direct Indexing L.P.’s holdings in IDEXX Laboratories were worth $1,115,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Glenmede Trust Co. NA grew its holdings in IDEXX Laboratories by 166.7% in the 3rd quarter. Glenmede Trust Co. NA now owns 3,595 shares of the company’s stock valued at $1,572,000 after buying an additional 2,247 shares in the last quarter. Advisors Asset Management Inc. raised its stake in IDEXX Laboratories by 9.6% in the 3rd quarter. Advisors Asset Management Inc. now owns 2,007 shares of the company’s stock worth $878,000 after purchasing an additional 176 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in IDEXX Laboratories by 51.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 225,150 shares of the company’s stock valued at $98,353,000 after purchasing an additional 76,350 shares during the period. Lido Advisors LLC increased its holdings in shares of IDEXX Laboratories by 33.8% during the third quarter. Lido Advisors LLC now owns 1,503 shares of the company’s stock worth $657,000 after purchasing an additional 380 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of IDEXX Laboratories by 8.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 801,274 shares of the company’s stock worth $350,373,000 after buying an additional 65,760 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Up 0.1 %

NASDAQ IDXX opened at $477.49 on Friday. The stock has a market capitalization of $39.44 billion, a P/E ratio of 46.22, a P/E/G ratio of 3.90 and a beta of 1.32. The business has a 50 day simple moving average of $500.62 and a 200 day simple moving average of $524.93. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.13. The company had revenue of $964.10 million during the quarter, compared to analyst estimates of $965.43 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. Research analysts expect that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Barclays lowered their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, June 14th. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Stifel Nicolaus cut their price objective on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a report on Monday, June 24th. Finally, Morgan Stanley lowered their target price on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a report on Tuesday, May 14th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $586.63.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Bruce L. Claflin sold 200 shares of IDEXX Laboratories stock in a transaction on Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the sale, the director now owns 161 shares of the company’s stock, valued at approximately $87,068.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 2.18% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.